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  EVIDENCE-BASED ANSWER 
Asymptomatic term infants whose mothers received adequate intrapartum antibiotic prophylaxis (defined as 
intravenous penicillin or ampicillin at least 4 hours before delivery) for group B streptococcal disease do not 
need work-up or treatment (strength of recommendation [SOR]: B, based on retrospective, population-based 
study). These infants should be observed for 48 hours, but may be discharged after 24 hours in circumstances 
where close follow-up is available (SOR: D, based on expert opinion). 
Symptomatic infants, premature infants (gestational age <35 weeks) of mothers who did not receive 
prophylaxis, and infants whose mothers had chorioamnionitis should receive a full evaluation (complete blood 
count, blood culture, and chest x-ray with or without a lumbar puncture) and an initial empiric antibiotic 
treatment with ampicillin or penicillin and gentamycin. If a term infant is not symptomatic and maternal antibiotic 
prophylaxis was not adequate, opinions differ as to whether to perform limited evaluation with empiric 
treatment or close observation (SOR: D, based on expert opinion). See Figure. 
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  EVIDENCE SUMMARY 
Intrapartum antibiotic prophylaxis has decreased the incidence of early-onset group B streptococcal disease by 
65% in the last decade.1 A multicenter population-based study demonstrated that basing prophylaxis on 
screening cultures is twice as effective as risk stratification, a previously recommended strategy.2 
Intrapartum prophylaxis of women who had positive group B streptococcal disease screening cultures at 35 
weeks will prevent 70% of earlyonset disease and 89% of fatalities.3,4 As demonstrated by multicenter 
retrospective studies, infants aged <35 weeks are at significantly higher risk of group B streptococcal disease 
than term infants (relative risk=1.5–2.07), and mortality for premature infants with early-onset disease (25%–
30%) is substantially higher than for term infants with early-onset disease (2%–8%).2,5 
A large retrospective study demonstrated that infants who developed early-onset disease despite intrapartum 
prophylaxis developed the same clinical syndrome in the same time frame (78% of early-onset disease evident 
in first 24 hours and 96% by 48 hours) as infants whose mothers did not receive prophylaxis.6 
The duration of adequate intrapartum antibiotic prophylaxis was initially set at 4 hours, based on a study 
measuring antibiotic penetration into amniotic fluid.7 A recent randomized trial, enrolling more than 4500 
women, has confirmed this finding. The vertical transmission rate of group B streptococcal disease, as 
measured by neonatal colonization (as opposed to clinical illness), is 46% when antibiotic prophylaxis is started 
<1 hour before delivery, 2.9% when prophylaxis is given at 2 to 4 hours, and 1.2% when given at least 4 hours 
before delivery.8 
Implementation of these guidelines is aided by the adoption of an institution-wide policy to support point of care 
decision-making.9 A retrospective study after the release of the 1996 Centers for Disease Control (CDC) 
guidelines concluded that hospitals with established group B streptococcal disease policies had significantly 
fewer cases of early-onset disease (P=.038).10 
  RECOMMENDATIONS FROM OTHERS 
The 2002 Prevention of Perinatal Group B Streptococcal Disease Revised Guidelines from the CDC states: “a 
healthy-appearing infant whose mother received >4 hours of [intrapartum antibiotic prophylaxis] before delivery 
may be discharged home as early as 24 hours after delivery, assuming other discharge criteria have been met 
and that a person able to comply fully with instructions for home observation will be present … if these 
conditions are not met, the infant should remain in the hospital for at least 48 hours of observation and until 
criteria for discharge are achieved.”1 
These guidelines strongly support universal prenatal screening and the use of intrapartum antibiotic 
prophylaxis. Both the American Academy of Pediatrics and the American College Obstetrics and Gynecology 
have endorsed the CDC’s revised guidelines. 
CLINICAL COMMENTARY 
Richard  Nicholas,  MD 
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The question of appropriate care of the infant exposed to group B streptococcal disease 
arises frequently in any practice caring for newborns. These clear, evidence-based 
recommendations are helpful in guiding that care. The evidence supports watchful waiting 
for appropriately covered newborns, providing reassurance for both parents and 
physicians. 
Unfortunately, little evidence exists to guide care in a setting that seems to be quite 
common: the term, asymptomatic infant born to a mother who, in labor, received less-
than-adequate intrapartum antibiotic prophylaxis. Further research for this subgroup is 
needed; in the meantime, physicians who provide maternity or newborn care should work 
together to develop protocols that ensure adequate intrapartum antibiotic coverage for 
mothers with group B streptococcal disease. 
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